BI
Jun 13, 2017
Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches
J&J's Invokana matches Jardiance's 14% reduction in major CV events There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it. In a cardiovascular outcomes trial, Johnson & Johnson's Invokana matched up to Eli Lilly and Boehringer...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
